SLR25Homo sapiens (Human)Cancer cell line
Also known as: SLR 25
AI Summary
No AI-generated summary available for this cell line.
Basic Information
| Database ID | CVCL_V611 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Not specified |
Donor Information
| Age Category | Unknown |
|---|---|
| Sex | Unknown |
Disease Information
| Disease | Clear cell renal carcinoma |
|---|---|
| Lineage | Kidney |
| Subtype | Renal Clear Cell Carcinoma |
| OncoTree Code | CCRCC |
DepMap Information
| Source Type | Academic lab |
|---|---|
| Source ID | ACH-000300_source |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Amelogenin
X
CSF1PO
11
D13S317
12
D16S539
12
D21S11
28,30
D5S818
12
D7S820
10,11
TH01
8,9.3
TPOX
8,12
vWA
17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines
Loading gene expression data...
Publications
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection.
Hsieh J.J.-D., Hakimi A.A.
Nat. Commun. 8:15165.1-15165.10(2017).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
Loss of PBRM1 expression is associated with renal cell carcinoma progression.
Pawlowski R., Muhl S.M., Sulser T., Krek W., Moch H., Schraml P.
Int. J. Cancer 132:E11-E17(2013).
Patterns of gene expression and copy-number alterations in von-Hippel Lindau disease-associated and sporadic clear cell carcinoma of the kidney.
Signoretti S.
Cancer Res. 69:4674-4681(2009).
Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma.
Kinch M.S., Ranieri E., Storkus W.J.
Cancer Res. 63:4481-4489(2003).